AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29096949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control management
Number of subjects: 244
Study 29096949 — intervention group
Group type: COMPARATOR
Intervention: Clinical management algorithm
Number of subjects: 244
Study 25572620 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive quitline (counselor-initiated calls)
Number of subjects: 427
Study 25572620 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive quitline (participant-initiated calls)
Number of subjects: 427
Study 24640697 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitomur (peptide bioregulator)
Number of subjects: 0
Study 24640697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21982309 — intervention group
Group type: EXPERIMENTAL
Intervention: MO.MA system (proximal protection)
Number of subjects: 53
Study 21982309 — intervention group
Group type: COMPARATOR
Intervention: FilterWire EZ (distal protection)
Number of subjects: 53
Study 18443259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bothersome hot flushes reported at baseline
Number of subjects: 3167
Study 18443259 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with baseline symptoms
Number of subjects: 3167
Study 18443259 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of symptoms after 3 years
Number of subjects: 3167
Study 18443259 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with symptom persistence
Number of subjects: 3167
Study 16805147 — intervention group
Group type: EXPERIMENTAL
Intervention: New bandage technology
Number of subjects: 15
Study 14640928 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (Aloxi)
Number of subjects: 0
Study 11019429 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg (three times a day)
Number of subjects: 688
Study 11019429 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 688
Study 11019429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688
Study 11019429 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (after switching from placebo)
Number of subjects: 688
Study 8841227 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir prophylaxis during late pregnancy
Number of subjects: 1818
Study 8841227 — intervention group
Group type: COMPARATOR
Intervention: Cesarean delivery for genital herpes lesions
Number of subjects: 1818
Study 8841227 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir followed by cesarean delivery if lesions occur
Number of subjects: 1818
Study 1584317 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (CA)
Number of subjects: 80
Study 1584317 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 80
Study 2867858 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 1mg/ethinyl estradiol 35 micrograms (NET/EE)
Number of subjects: 847
Study 2867858 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms/ethinyl estradiol 30 micrograms (LNG/EE)
Number of subjects: 847
Study 2867858 — intervention group
Group type: COMPARATOR
Intervention: IUD (comparison group)
Number of subjects: 847
Study 30986402 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-inch diagonal video monitor
Number of subjects: 1795
Study 30986402 — intervention group
Group type: COMPARATOR
Intervention: 19-inch diagonal video monitor
Number of subjects: 1795
Study 29105871 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized and tailored letter from the GP and a personal invitation and appointment to attend a taster session providing information about SSS
Number of subjects: 4384
Study 29105871 — intervention group
Group type: COMPARATOR
Intervention: Standard generic letter from the GP advertising SSS
Number of subjects: 4384
Study 27130912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh group - lightweight monofilament mesh (<50g/m(2)) inserted in a sublay location during end-colostomy creation.
Number of subjects: 200
Study 27130912 — intervention group
Group type: COMPARATOR
Intervention: Conventional stoma formation (control group).
Number of subjects: 200
Study 23620494 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC1)
Number of subjects: 0
Study 23620494 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (CONC)
Number of subjects: 0
Study 23620494 — intervention group
Group type: COMPARATOR
Intervention: Repeated eccentric exercise (ECC2)
Number of subjects: 0
Study 23134097 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge warfarin management service with pharmacist education during two or three home visits.
Number of subjects: 268
Study 23134097 — intervention group
Group type: COMPARATOR
Intervention: Usual community-based post-discharge care.
Number of subjects: 268
Study 20607877 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 24
Study 20607877 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 24
Study 20607877 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 24
Study 18389448 — intervention group
Group type: EXPERIMENTAL
Intervention: Guide-wire cannulation
Number of subjects: 413
Study 18389448 — intervention group
Group type: COMPARATOR
Intervention: Contrast cannulation
Number of subjects: 413
Study 15558237 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 145
Study 15558237 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 145
Study 14602503 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg, t.i.d.)
Number of subjects: 66
Study 14602503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 10191137 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2.5 mg
Number of subjects: 5
Study 10191137 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 5
Study 10191137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 8564107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1.5 mg inhaled daily for 8 weeks
Number of subjects: 17
Study 8664173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (Group A: smokers vs nonsmokers)
Number of subjects: 289
Study 8664173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (Group B: smokers vs nonsmokers)
Number of subjects: 289
Study 8664173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (Group A and B: smokers vs nonsmokers)
Number of subjects: 289
Study 3537268 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline sulfate (0.25 mg) administered to 43/85 (50.5%) of ECV candidates
Number of subjects: 85
Study 3537268 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 85
Study 3537268 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful ECV
Number of subjects: 85
Study 3537268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 85
Study 3537268 — intervention group
Group type: COMPARATOR
Intervention: ECV failure
Number of subjects: 85
Study 3537268 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium aspiration
Number of subjects: 85
Study 30440139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesogastrium excision above the pancreas by the right approach (n=78)
Number of subjects: 154
Study 30440139 — intervention group
Group type: COMPARATOR
Intervention: Mesogastrium excision above the pancreas by the left approach (n=76)
Number of subjects: 154
Study 27739067 — intervention group
Group type: EXPERIMENTAL
Intervention: CAREPATH intervention (depression care management)
Number of subjects: 755
Study 27739067 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 755
Study 24183344 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin glue (PRFG)
Number of subjects: 145
Study 24183344 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PRFG approach)
Number of subjects: 145
Study 24183344 — intervention group
Group type: EXPERIMENTAL
Intervention: PRFG in PS-matched cohort
Number of subjects: 145
Study 23321171 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 186
Study 23321171 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 186
Study 20865240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (200 mg/day)
Number of subjects: 20
Study 20865240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 18000175 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on log‐BMI, age, log‐fasting C‐peptide, and postchallenge glucose and C‐peptide sums from 2‐h oral glucose tolerance tests (OGTTs)
Number of subjects: 670
Study 18000175 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score additionally dependent on a decreased first‐phase insulin response variable from intravenous glucose tolerance tests (IVGTTs)
Number of subjects: 670
Study 18000175 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the type 1 diabetes risk score from baseline to 1 year
Number of subjects: 670
Study 15871851 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg/day)
Number of subjects: 86
Study 15871851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20mg/day)
Number of subjects: 86
Study 12832364 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic SCT (n = 23)
Number of subjects: 45
Study 12832364 — intervention group
Group type: COMPARATOR
Intervention: Autologous SCT (n = 22)
Number of subjects: 45
Study 12832364 — intervention group
Group type: COMPARATOR
Intervention: Allo-SCT with cGVHD (n = 13)
Number of subjects: 45
Study 12832364 — intervention group
Group type: COMPARATOR
Intervention: Combined group of SCT patients (allo + auto)
Number of subjects: 45
Study 10208315 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐nicotine vapor (40, 80, 120, 160 ng/ml)
Number of subjects: 0
Study 10208315 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)‐nicotine vapor (40, 80, 120, 160 ng/ml)
Number of subjects: 0
Study 10208315 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory detection threshold for 'odorous' sensation (not specified)
Number of subjects: 0
Study 8023964 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine + Aldosterone
Number of subjects: 12
Study 8023964 — intervention group
Group type: COMPARATOR
Intervention: Aldosterone alone
Number of subjects: 12
Study 2493302 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 5 megaunits (MU) daily for one week, reducing to 5 MU thrice weekly for seven weeks, then 3 MU thrice weekly for eight weeks
Number of subjects: 14
Study 2493302 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 769484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepiprazol (EMD 16.923)
Number of subjects: 8
Study 769484 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 8
Study 30818406 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring
Number of subjects: 40
Study 30818406 — intervention group
Group type: COMPARATOR
Intervention: Blinded continuous glucose monitoring
Number of subjects: 40
Study 29241306 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC intake + SDP
Number of subjects: 10
Study 29241306 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA intake + SDP
Number of subjects: 10
Study 29241306 — intervention group
Group type: EXPERIMENTAL
Intervention: SDP conditions
Number of subjects: 10
Study 29241306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined and isolated ALC intake and one night of SDP
Number of subjects: 10
Study 29241306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of ALC intake and SDP
Number of subjects: 10
Study 25138128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 140
Study 25138128 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 140
Study 23246389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with 1 to 10 participants
Number of subjects: 4133
Study 23246389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with 11 to 30 participants
Number of subjects: 4133
Study 23246389 — intervention group
Group type: COMPARATOR
Intervention: Sites with >30 participants
Number of subjects: 4133
Study 23246389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with 1 to 10 participants (adjusted for risk factors)
Number of subjects: 4133
Study 23246389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with 11 to 30 participants (adjusted for risk factors)
Number of subjects: 4133
Study 23246389 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol completion rates
Number of subjects: 4133
Study 21376564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil patient-controlled analgesia
Number of subjects: 20
Study 21376564 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine/sufentanil
Number of subjects: 20
Study 19051552 — intervention group
Group type: EXPERIMENTAL
Intervention: Procera all-ceramic copings
Number of subjects: 0
Study 19051552 — intervention group
Group type: COMPARATOR
Intervention: Cerec-in-lab copings
Number of subjects: 0
Study 19051552 — intervention group
Group type: COMPARATOR
Intervention: IPS Empress 2 copings
Number of subjects: 0
Study 16834525 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug laboratory monitoring alerts within the CPOE system
Number of subjects: 207
Study 16834525 — intervention group
Group type: COMPARATOR
Intervention: No alerts (Control)
Number of subjects: 207
Study 12767083 — intervention group
Group type: COMPARATOR
Intervention: FAC (5-fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 789
Study 12767083 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC + MV (methotrexate and vinblastine)
Number of subjects: 789
Study 12767083 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 789
Study 12767083 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC + MV (in Group 2)
Number of subjects: 789
Study 10799352 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamillosan(R) cream
Number of subjects: 0
Study 10799352 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hydrocortisone cream
Number of subjects: 0
Study 10799352 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 0
Study 9277559 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake (1,800 mg/day)
Number of subjects: 5
Study 9277559 — intervention group
Group type: COMPARATOR
Intervention: Control calcium intake (800 mg/day)
Number of subjects: 5
Study 8426248 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 36
Study 8426248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2442610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) 0.5 ml/kg body weight, administered intramuscularly at 2, 6, and 10 months of age.
Number of subjects: 703
Study 2442610 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) 0.5 ml/kg body weight, administered intramuscularly at 2, 6, and 10 months of age.
Number of subjects: 703
Study 29650803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158
Study 29650803 — intervention group
Group type: COMPARATOR
Intervention: Control (Self-Monitoring of Blood Glucose)
Number of subjects: 158
Study 29650803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime analysis of CGM
Number of subjects: 158
Study 29650803 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sensor use from 7 to 10 days
Number of subjects: 158
Study 26469356 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS), administered twice daily for 8 weeks
Number of subjects: 80
Study 26469356 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 8 weeks
Number of subjects: 80
Study 25503546 — intervention group
Group type: EXPERIMENTAL
Intervention: a-NIHSS item profiles
Number of subjects: 10271
Study 25503546 — intervention group
Group type: EXPERIMENTAL
Intervention: b-NIHSS item profiles
Number of subjects: 10271
Study 23053462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachway intubating stylet
Number of subjects: 38
Study 23053462 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 38
Study 20348164 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (modified TTBA)
Number of subjects: 45
Study 20348164 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (modified TTBA) - Early treatment group
Number of subjects: 45
Study 20348164 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (modified TTBA) - Late treatment group
Number of subjects: 45
Study 20348164 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed without treatment for 8 months)
Number of subjects: 45
Study 18227988 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point AUC (AUCp) for vitamin A-fortified skim milk
Number of subjects: 19
Study 18227988 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point AUC (AUCp) for whole milk
Number of subjects: 19
Study 18227988 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point AUC (AUCp)
Number of subjects: 19
Study 18227988 — intervention group
Group type: COMPARATOR
Intervention: 7-point AUC (AUCc)
Number of subjects: 19
Study 16598414 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified POPQ exam
Number of subjects: 48
Study 14711187 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode pad position over the right lower sternal border-left infrascapular area (AP group, n = 39)
Number of subjects: 70
Study 14711187 — intervention group
Group type: COMPARATOR
Intervention: Electrode pad position over the ventricular apex-right infraclavicular area (AL group, n = 31)
Number of subjects: 70
Study 14711187 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients as a group
Number of subjects: 70
Study 11778530 — intervention group
Group type: EXPERIMENTAL
Intervention: Local chemotherapy by fibrobronchoscopy with carboplatin 300 mg combined with intravenous chemotherapy (carboplatin and etoposide regimen)
Number of subjects: 40
Study 11778530 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy with routine carboplatin and etoposide regimen
Number of subjects: 40
Study 8668877 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable gold
Number of subjects: 44
Study 8668877 — intervention group
Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 44
Study 1510170 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt without neck suction
Number of subjects: 8
Study 1510170 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilt with neck suction (23 +/- 1 mmHg)
Number of subjects: 8
Study 1510170 — intervention group
Group type: COMPARATOR
Intervention: Neck suction
Number of subjects: 8
Study 7056070 — intervention group
Group type: EXPERIMENTAL
Intervention: Drionic device treatment for hyperhidrosis
Number of subjects: 0
Study 7056070 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline sweat print of 1)
Number of subjects: 0
Study 29501349 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on left M1
Number of subjects: 10
Study 29501349 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 29087231 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (25 mg)
Number of subjects: 0
Study 29087231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26894651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 381
Study 26894651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 381
Study 26894651 — intervention group
Group type: COMPARATOR
Intervention: Control (Donor-recipient Cytomegalovirus mismatch)
Number of subjects: 381
Study 24292257 — intervention group
Group type: EXPERIMENTAL
Intervention: NG/NJT placement
Number of subjects: 270
Study 24292257 — intervention group
Group type: COMPARATOR
Intervention: no-NG/NJT placement
Number of subjects: 270
Study 22123358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) 30 mg
Number of subjects: 83
Study 22123358 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (FURO) 80 mg
Number of subjects: 83
Study 22123358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) 30 mg and Furosemide (FURO) 80 mg
Number of subjects: 83
Study 22123358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 19770596 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised neck/shoulder exercise regimen
Number of subjects: 68
Study 19770596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise regimen)
Number of subjects: 68
Study 16847014 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 100
Study 16847014 — intervention group
Group type: COMPARATOR
Intervention: Mini incision open donor nephrectomy
Number of subjects: 100
Study 14967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Iseganan oral solution plus standard-of-care oral hygiene (SOC)
Number of subjects: 545
Study 14967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus standard-of-care oral hygiene (SOC)
Number of subjects: 545
Study 14967419 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care oral hygiene (SOC) alone
Number of subjects: 545
Study 11055776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercurius solubilis
Number of subjects: 104
Study 9381995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 38
Study 8258082 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview (TEL)
Number of subjects: 1000
Study 8258082 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation (STD)
Number of subjects: 1000
Study 3723570 — intervention group
Group type: EXPERIMENTAL
Intervention: Critiques from preceptors
Number of subjects: 105